A recent National Institutes of Health State-of-the-Science Conference 1 "Manifestations and Management of Chronic Insomnia in Adults," noted that "insomnia is the most common sleep complaint across all stages of adulthood, and for millions, the problem is chronic." The panel concluded that "there is great need for additional research to better define the nature of chronic insomnia." While recognizing evidence from both psychological and physiologic models in the etiology of insomnia, the conference encouraged more research by concluding that "the neural mechanisms underlying chronic insomnia are poorly understood" and that "studies aiming to identify neural mechanisms should use animal models and in vivo neural imaging approaches in people with insomnia and in individuals with normal sleep."
SCIENTIFIC INVESTIGATIONS
Study Objective: To investigate the non-rapid eye movement (NREM) sleep-related regional cerebral metabolic correlates of wakefulness after sleep onset (WASO) in patients with primary insomnia. Methods: Fifteen patients who met DSM-IV criteria for primary insomnia completed 1-week sleep diary (subjective) and polysomnographic (objective) assessments of WASO and regional cerebral glucose metabolic assessments during NREM sleep using [ 18 F] fluoro-2-deoxy-D-glucose positron emission tomography. Whole-brain voxel-by-voxel correlations, as well as region of interest analyses, were performed between subjective and objective WASO and relative regional cerebral metabolism using the statistical software SPM2. Results: Subjective WASO was significantly greater than objective WASO, but the 2 measures were positively correlated. Objective WASO correlated positively with the percentage of stage 2 sleep and negatively with the percentage of stages 3 and 4 sleep. Both subjective and objective WASO positively correlated with NREM sleep-related cerebral glucose metabolism in the pontine tegmentum and in thalamocortical networks in a frontal, anterior temporal, and anterior cingulate distribution. Conclusions: Increased relative metabolism in these brain regions during NREM sleep in patients with insomnia is associated with increased WASO measured either subjectively or objectively. These effects are related to the lighter sleep stages of patients with more WASO and may result from increased activity in arousal systems during sleep and/or to activity in higher-order cognitive processes related to goal-directed behavior, conflict monitoring, emotional awareness, anxiety, and fear. Such changes may decrease arousal thresholds and/or increase perceptions of wakefulness in insomnia. 
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brainstem, hypothalamic/basal forebrain, and limbic networks, as compared with good sleepers, suggesting involvement of basic sleep-wake-regulatory centers and emotion centers in the pathophysiology of insomnia. 3 This functional neuroanatomic model of hyperarousal is consistent with the emotional and physiologic hyperarousal of insomnia reported in several other studies using a variety of methods (e.g., [4] [5] [6] [7] [8] ). In the current study, we sought to extend our understanding of the neurobiology of sleep in insomnia by more specifically analyzing the NREM-sleep-related cerebral metabolic correlates of sleep disturbances. We began by studying the most common complaint of patients with insomnia, sleep maintenance problems, as indexed by wakefulness after sleep onset (WASO). Because subjective sleep complaints in patients with insomnia do not always match objective sleep disturbances as measured by conventional polysomnography (PSG) 3 , we assessed both subjective and objective measures of WASO and identified their cerebral metabolic correlates independently. Because WASO may reflect subcortical "waking" experiences that do not have a 1:1 correlation with cortically recorded electroencephalography (EEG), we hypothesized that subjective measures of WASO would exceed objective measures of WASO and that both measures of WASO would correlate with lighter stages of NREM sleep and a generalized increase in thalamocortical metabolism within sleep. Increased thalamocortical metabolism could be the final common pathway of abnormalities at 1 or multiple levels of an arousal hierarchy. 2 In other words, we hypothesized that WASO may act as a surrogate marker of brain arousal during NREM sleep, as measured by metabolic activity. We used the [ 18 F]-fluorodeoxyglucose (FDG ) positron emission tomography (PET) method 9 to assess regional cerebral glucose metabolism during NREM sleep as a measure of thalamocortical metabolic activity. Voxel-by-voxel analyses across the brain were performed to define if there were specific thalamocortical regions in which relative metabolism correlated with WASO, both subjectively and objectively.
METHODS
Subjects were fifteen patients with primary insomnia (7 women / 8 men, mean age ± SD = 36.9 ± 10.5 years) recruited from the public by advertisements. After complete description of the study to the patients, written informed consent was obtained. In order to ensure a sample of patients with primary insomnia reflecting clinical practice, our criteria were based entirely on subjective reports assessed in a standardized fashion. 10 Patients with insomnia were required to meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for primary insomnia as indicated by (1) a complaint of difficulty falling asleep, staying asleep, or nonrestorative sleep; (2) duration of the complaint of at least 1 month; (3) the sleep disturbance causes clinically significant distress or impairment; (4) insomnia that does not occur exclusively during the course of a mental disorder; and (5) insomnia not due to another medical or sleep disorder, or effects of medications/substance abuse. Patients were required to have a global score on the Pittsburgh Sleep Quality Index (PSQI) 11 of at least 7, in order to ensure a minimum level of severity. Patients were not required to meet specific criteria for WASO by subjective or objective measure; their sleep complaint could include any combination of difficulty falling asleep, staying asleep, or nonrestorative sleep. These criteria were chosen to reflect insomnia in clinical practice, as opposed to insomnia in most clinical trials, and no PSG qualifying criteria were required. Nightly urine drug screens were obtained during the sleep study to ensure abstinence from substances of abuse. Potential participants were excluded from participation if they were using any medications that might affect sleep or regional cerebral metabolism, including hypnotics. Patients were also excluded for any of the following: irregular sleep schedules associated with shift work, frequent travel, or personal preference as indicated by weekly variation of more than 3 hours in bed time or wake time, or time in bed duration less than 5.5 or more than 10 hours per night; reported excessive use of caffeine (> 300 mg or 3 cups of coffee per day); current (within past 6 months) major depressive disorder or other mental disorder on the basis of a Structured Clinical Interview for DSM-IV. 3, 12, 13 Sleep quality and daytime mood and function were assessed using the PSQI 11 and the Profile of Mood States (POMS). 14 Subjective WASO was measured using a standardized 1-week diary in which patients reported the number of minutes of wakefulness each night. 15 The mean nightly WASO (minutes) was used in further analyses. Sleep was monitored with EEG on 3 consecutive nights using standard methods.
3,12,13 Night 1 was used as an adaptation night and for screening other sleep disorders such as sleep apnea and periodic limb movement disorder. Night 2 records were scored visually for sleep staging in 20-second epochs 16 ; results from Night 2 were used in PET correlation analyses. Regional cerebral glucose metabolism was assessed during NREM sleep on night 3 using the [ 18 F]-FDG PET method. 9 The NREM PET scan reflected brain activity over a 20-minute period beginning 20 minutes after sleep onset. Image analysis included statistical parametric mapping (SPM2).
17
A paired-samples t-test was used to assess differences between subjective and objective measures of WASO. Correlational analyses were used to quantify relationships between WASO and specific stages of NREM sleep, as well as with microarousals. Correlational analyses were used to quantify relationships between subjectively and objectively measured WASO and regional cerebral metabolism of deoxyglucose (MRDglc) after controlling for variability related to global metabolism using the Statistical Parametric Mapping program. 17 Statistical maxima were identified by their Talairach atlas (x, y, z axis) coordinates. 18 Based on theoretical models of sleep regulation, additional 10-mm spherical regions of interest were identified in the areas of the thalamus, pontine tegmentum, and hypothalamus/basal forebrain. Correlational analyses were also performed in these regions using the small-volume corrections feature in SPM2.
RESULTS
Clinical and sleep measures for the study sample are shown in Table 1 . As defined by entry into the study, insomnia patients reported poor sleep quality (PSQI score = 12.7 ± 4.0). Subjective diary and objective PSG measures of sleep for the insomnia group are also provided in Table 1 . The mean ± SD subjective WASO across patients was 49 ± 35 minutes (range 6 to 124 minutes). The mean ± SD PSG WASO across patients was 29 ± 27 minutes (range 5 to 105 minutes). The mean ± SD subjective WASO was greater than the mean ± SD objective WASO (t = -3.0, df = 14, p = .01). However, subjective WASO positively correlated with objective WASO (r = .69, p = .004).
Relationship Between WASO and Other PSG Measures
Sleep neuroimaging studies have previously shown differences in brain activity depending on the stage of NREM sleep measured (e.g., stages 1, 2, 3, or 4 sleep), and, thus, the degree to which WASO correlates with different stages of NREM sleep might affect metabolic patterns observed. We hypothesized that WASO would positively correlate with percentages of "lighter" stages of sleep, such as stages 1 and 2 sleep, and negatively correlate with Sleep staging during the [18F]-FDG 20-minute uptake period was predominantly NREM sleep with a mean of only 1.3 minutes of wakefulness (see Table 1 for minutes in each stage and Figure  1 for epoch-by-epoch amounts of sleep stages for all subjects). In terms of NREM sleep staging, the [18F]-FDG 20-minute uptake period reflected predominantly stages 2, 3, and 4 sleep. We repeated the SPM analyses below after excluding any subject who demonstrated any wakefulness during the 20-minute NREM FDG uptake period (n = 7 subjects remaining) and found a similar regional distribution of results. Further, objective WASO from night 2 did not correlate with either stage 1 sleep or with microarousals during the uptake period. Therefore, correlations between WASO and PET-measured MRDglc are unlikely to reflect the effects of waking during the uptake period.
After controlling for differences in whole-brain metabolism, a correlational analysis was then performed on a regional voxelby-voxel basis across the entire brain using SPM2 (see Figures 2a  and 3 ). Subjective WASO positively correlated with regional cerebral metabolism during NREM sleep in broad expanses of frontal cortex, dorsal anterior cingulate, and medial prefrontal cortex (Figure 2b) . The results show a similar distribution (see Figures 2a and b) .
DISCUSSION
Increased WASO from a baseline night of sleep in patients with insomnia was related to increased relative pontine and thalamocortical metabolism during NREM sleep. The distribution of this increase was broad and included the pontine tegmentum, thalamus, frontal, anterior cingulate, and temporal cortex. Similar correlation patterns were identified for subjective and PSG WASO despite the difference in mean WASO identified by diary and PSG. This pattern of increased glucose metabolic activity in the central nervous system is consistent with the emotional and physiologic hyperarousal of insomnia reported in several other studies using questionnaire, neuroendocrine, EEG, and wholebody metabolic-rate measures (e.g., [4] [5] [6] [7] [8] ). The current findings are consistent with those from prior sleep neuroimaging studies that have examined the relationships between the depth of NREM sleep and cerebral activity. [19] [20] [21] [22] In those studies, greater decreases in cortical activity were associated with deeper stages of sleep on a continuum from stage 1 to stage 4. In this context, the increased cortical metabolism in patients with insomnia who exhibit more WASO is likely related to the fact that the patients also had relatively lighter stages of sleep, such as stage 2 sleep, during the [18F]-FDG uptake period, as compared with those with lesser amounts of WASO. The fact that there was significant stability of individual sleep-staging profiles from night to night in this insomnia sample raises the possibility that this lighter sleep is a stable feature.
The current study demonstrates associations between metabolism in different brain regions and amount of WASO in an insomnia sample. These results may reflect a downstream, or bottomup, effect of increased activity in basic sleep-wake-regulating areas such as the brainstem and hypothalamus. Alternatively, these results may reflect a top-down effect of activity in cortical regions that participate in higher-order cognitive and emotional behavior and that may influence arousal areas of the brainstem and hypothalamus. Either of these scenarios is consistent with existing theoretic models of sleep disturbances in insomnia. 2, 23 The regions in which NREM-sleep metabolism showed a positive correlation with self-reported WASO are associated with goaldirected behavior, conflict monitoring, and emotional awareness, possibly involving anticipatory anxiety or fear. The thalamus has consistently demonstrated alterations in activity across the wake-NREM-sleep continuum, with decreased activity associated with NREM sleep or fatigue and sleepiness and increased activity associated with alert waking. 24, 25, 26 The prefrontal cortex has been shown to play an important role in executive function, including selective attention, planning, and effortful regulation of affective states. 27, 28 Although the frontal cortex showed the observed correlation bilaterally, some right hemispheric tendency was noted. Davidson has emphasized the importance of left-lateralized prefrontal cortical regions in approach-related appetitive goals and the right in behavioral inhibition and vigilant attention. 29 Involvement of the right prefrontal cortex during NREM sleep in patients with insomnia in relation to increasing WASO may signify involvement of behavioral inhibition and vigilant attention within sleep that disrupts sleep maintenance.
Metabolism in the anterior cingulate cortex, especially in the Brain Correlates of WASO in Insomnia pregenual and dorsal supragenual components, positively correlated with WASO. The rostral pregenual part of the anterior cingulate cortex has been more strongly implicated in the evaluation of emotional information (e.g., 30, 31 ). The dorsal supragenual anterior cingulate cortex has been associated with conflict monitoring (e.g., it is particularly active during conditions when one must arbitrate quickly between 2 likely responses 32 ). Thus, cognitive processes related to conflict monitoring and emotional evaluation during NREM sleep may be related to the amount of subjective or objective WASO. The temporal lobes, especially the temporal poles, have been associated with emotional awareness, anticipatory anxiety in generalized social phobia, 33 and an affect-sensitive fear network. 34 Involvement of the temporal lobes during sleep in patients with insomnia in relation to increasing WASO may signify involvement of cognitive processes related to emotional awareness, fear, or anticipatory anxiety.
The relationship between WASO and cortical metabolism in the PET scans could simply reflect wakefulness during the radio- isotope uptake period. We do not believe this is the case for several reasons. First, neither the amount of waking during the FDG uptake periods nor the number of microarousals correlated with diary measures of WASO (r = .02, p = .94). Indeed, the subject with the most WASO did not have any wake during the NREM [18F]-FDG 20-minute uptake period. Second, all subjects were asleep throughout the initial 10-minute uptake period when FDG uptake and metabolism in the brain is maximal. Third, after we excluded subjects with any trace amounts of wakefulness during the 20-minute uptake period from the analyses, the regional correlations between WASO and relative metabolism remained. For these reasons, we believe that WASO in patients with insomnia is associated with cerebral metabolic patterns during true NREM sleep that reflect more-subtle forms of arousal. This is consistent with the positive correlations between WASO and stage 2 sleep and the negative correlations between WASO and stages 3/4 sleep in the current sample.
Finally, the current results shed light on controversies regarding the sleep-state misperceptions of patients with insomnia. The current study replicates prior work in showing that patients with insomnia tend to subjectively overestimate the sleep-maintenance disruptions they have, when compared with PSG measures. Still, subjective and objective measures of sleep-maintenance disturbances were positively correlated, and the correlations of each with regional cerebral metabolism showed similar overall brain patterns. This suggests that these subjects, in fact, accurately perceive some aspect of brain function that is process-like in its effects but is measured as having state-like normality by conventional PSG methods. In such a case, findings about cerebral metabolic patterns more typical of wakefulness would be salient in relevant brain regions with the increasing severity of sleep complaints.
Some caveats are worth noting. First, the current patients with insomnia were not selected using quantitative criteria for subjective WASO, PSG WASO, or other specific sleep parameters. Overall, the severity of diary and PSG sleep disturbances was mild compared, as with samples selected on the basis of specific quantitative criteria. However, our sample is more likely to be similar to actual clinical patients, in whom quantitative criteria are not routinely applied. Moreover, the fact that our findings result from correlation analyses suggests that the WASO-brain metabolism relationship is a continuous one. Examining good sleepers and patients more severely affected by insomnia would help to further clarify this relationship. Second, the WASO used in these analyses was collected on different nights than was regional brain metabolism. This may have served to weaken the observed associations. On the other hand, it is important to emphasize that the correlations were between WASO and regional metabolism during NREM sleep. Therefore, it would be appropriate to view our results as identifying brain-activity patterns during sleep that correlated with and, perhaps, predispose to WASO. Third, a healthy, good-sleeper, control group was not studied. The relationship observed between WASO and cerebral metabolism may not be specific to insomnia. Indeed, we believe that continuous declines in cortical metabolism would be observed in healthy subjects as they descend from lighter stages 1 and 2 sleep into deeper stages 3 and 4 sleep across the night.
